Study identifier:D1060C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers with Lung Metastasis in the Expansion Phase.
solid malignancies
Phase 1
No
AZD1480
All
38
Interventional
18 Years - 99 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2014 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD1480 until Maximum Tolerated Dose (MTD) is reached | Drug: AZD1480 continuous daily oral capsule |
Experimental: 2 AZD1480 dose expansion of MTD | Drug: AZD1480 continuous daily oral capsule |